What Is Thymogen?
Thymogen is a synthetic dipeptide bioregulator with the sequence Glu‑Trp (EW), originally isolated as one of the active short peptides within the thymus extract Thymalin and later synthesized as a defined molecule. As one of the smallest effective thymic peptides, it retains a potent immunomodulatory profile despite its minimal size, and has been approved for clinical use in Russia for immune deficiency conditions associated with aging, chemotherapy, and chronic infections. It was developed by Prof. Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology.
Important distinction: Thymogen (EW dipeptide) is different from Thymogen Alpha‑1 (an oral combination supplement pairing Thymogen with Lys‑Glu) and from Thymosin α1 (Thymalfasin, a 28-amino acid drug for hepatitis B). In Western markets, Thymogen EW is available only as a research chemical or supplement.
Key Benefits
- Normalizes T/B lymphocyte ratios in immunodeficient states
- Stimulates IL-2 production and NK cell cytotoxicity
- Enhances macrophage phagocytic activity
- Supports hematopoiesis and post-trauma regeneration
- Bidirectional immune modulation — activates without overstimulation
Mechanism of Action
Thymogen activates thymic epithelial cell signaling pathways that promote T-lymphocyte maturation and differentiation. Khavinson's group describes short peptides like Thymogen as interacting directly with complementary DNA promoter sequences to regulate gene expression for cytokines, heat-shock proteins, fibrinolysis, and cell differentiation — effectively functioning as an epigenetic regulator of thymic immune programs.
Quick Reference
Member reference tables summarize the compound's research parameters.
Research Indications
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below), not a personal dosing recommendation.
This member section describes parameters reported in the research literature.
Peptide Interactions
This member section summarizes reported compound interactions and evidence limitations.
Reported Research Time Points
This member section summarizes reported research time points.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
This member section discusses research safety considerations and uncertainties.
Quality Indicators
Research Citations
- The First Reciprocal Activities of Chiral Peptide Pharmaceuticals: Thymogen and Thymodepressin, as Examples
Deigin V, Linkova N, Vinogradova J, 2024, Int J Mol Sci - Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line
Avolio F, Martinotti S, Khavinson VK, 2022, Int J Mol Sci - Chemical Platform for the Preparation of Synthetic Orally Active Peptidomimetics with Hemoregulating Activity
Deigin V, Ksenofontova O, Khrushchev A, 2016, ChemMedChem - [Influence of peptides from pineal gland on thymus function at aging]
Lin'kova NS, Poliakova VO, Trofimov AV, 2010, Adv Gerontol - Novel platform for the preparation of synthetic orally active peptidomimetics with hemoregulating activity. II. Hemosuppressor activity of 2,5-diketopiperazine-based cyclopeptides
Deigin V, Ksenofontova O, Yatskin O, 2020, Int Immunopharmacol - Khavinson development attribution. Avolio et al. Int J Mol Sci. 2022;23(7):3607. Khavinson peptide attribution.
Thymogen is a synthetic dipeptide bioregulator with the sequence Glu‑Trp (EW), originally isolated as one of the active short peptides within the thymus extract Thymalin and later synthesized as a defined molecule. As one of the smallest effective thymic peptides, it retains a potent immunomodulatory profile despite its minimal size, and has been approved for clinical use in Russia for immune deficiency conditions associated with aging, chemotherapy, and chronic infections.